CA3010977A1 - Novel cross protective vaccine compositions for porcine epidemic diarrhea virus - Google Patents

Novel cross protective vaccine compositions for porcine epidemic diarrhea virus Download PDF

Info

Publication number
CA3010977A1
CA3010977A1 CA3010977A CA3010977A CA3010977A1 CA 3010977 A1 CA3010977 A1 CA 3010977A1 CA 3010977 A CA3010977 A CA 3010977A CA 3010977 A CA3010977 A CA 3010977A CA 3010977 A1 CA3010977 A1 CA 3010977A1
Authority
CA
Canada
Prior art keywords
vaccine compositions
epidemic diarrhea
porcine epidemic
diarrhea virus
cross protective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3010977A
Other languages
French (fr)
Inventor
Marta Cabana Sumsi
Monica Balasch Sanuy
Laia Plaja Dilme
Alicia Urniza Hostench
Paul J. Dominowski
Jay Gregory Calvert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of CA3010977A1 publication Critical patent/CA3010977A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20064—Methods of inactivation or attenuation by serial passage

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention is directed to novel isolates of porcine epidemic diarrhea virus (PEDV) and vaccine compositions made therefrom. The vaccine compositions protect swine from PED disease, and are cross protective against a wide variety of strains, whether variant or prototype, that currently circulate throughout the world. The vaccines are provided in both killed and live virus forms, as derived from strain Calaf14, and suggest specific amino acid modifications to the encoding sequences of all other PEDV strains that may improve their performance as vaccines.. Novel culture methods are also employed to increase reproducible yield of cultured viruses.
CA3010977A 2016-01-11 2016-01-11 Novel cross protective vaccine compositions for porcine epidemic diarrhea virus Abandoned CA3010977A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/012899 WO2017123201A1 (en) 2016-01-11 2016-01-11 Novel cross protective vaccine compositions for porcine epidemic diarrhea virus

Publications (1)

Publication Number Publication Date
CA3010977A1 true CA3010977A1 (en) 2017-07-20

Family

ID=55358111

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3010977A Abandoned CA3010977A1 (en) 2016-01-11 2016-01-11 Novel cross protective vaccine compositions for porcine epidemic diarrhea virus

Country Status (3)

Country Link
EP (1) EP3402878A1 (en)
CA (1) CA3010977A1 (en)
WO (1) WO2017123201A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108060139B (en) * 2017-08-31 2021-07-20 浙江美保龙生物技术有限公司 Isolation culture method of porcine epidemic diarrhea virus
CN107446894A (en) * 2017-09-15 2017-12-08 天津瑞普生物技术股份有限公司 A kind of Porcine epidemic diarrhea virus preparation method
CN112867505A (en) * 2018-09-20 2021-05-28 勃林格殷格翰动物保健有限公司 Modified PEDV spike protein
CN110894216B (en) * 2019-11-21 2022-03-08 河北农业大学 Porcine epidemic diarrhea virus epitope peptide, monoclonal antibody and application
CN114438040A (en) * 2020-11-04 2022-05-06 中山大学 Monoclonal cell strain secreting antibody with PEDV (porcine epidemic diarrhea Virus) neutralizing activity and application thereof
CN115074334B (en) * 2021-03-15 2024-01-19 夏津新希望六和农牧有限公司 Porcine epidemic diarrhea virus strain, amplification culture method, vaccine composition prepared from porcine epidemic diarrhea virus strain, preparation method and application of porcine epidemic diarrhea virus strain and amplification culture method
CN114931648B (en) * 2022-06-15 2024-02-27 金宇保灵生物药品有限公司 Heat-resistant protective agent for combined live vaccine against porcine epidemic diarrhea and transmissible gastroenteritis, and preparation method and application thereof
CN117286162A (en) * 2023-04-14 2023-12-26 扬州大学 Recombinant porcine delta coronavirus infectious clone and construction method and application thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
JPH07507854A (en) 1991-12-23 1995-08-31 ツォッヒェ，ミヒャエル Engine with oil removal device
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
KR100780158B1 (en) 1996-10-23 2007-11-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Immunotherapy and Improved Vaccines
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
KR20070039615A (en) 1998-02-27 2007-04-12 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Vaccines, immunotherapeutics and methods for using the same
WO2000018434A1 (en) 1998-09-30 2000-04-06 American Cyanamid Company Mutant cholera holotoxin as an adjuvant
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
ATE451386T1 (en) 2001-06-07 2009-12-15 Wyeth Corp MUTANT FORMS OF CHOLERA HOLOTOXIN AS ADJUVANTS
EP1404279A4 (en) 2001-06-07 2007-08-08 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
BR0313806A (en) 2002-08-26 2005-07-05 Pfizer Prod Inc Vaccines for infections in the respiratory and reproductive systems in cattle
KR100502008B1 (en) 2003-04-29 2005-07-18 녹십자수의약품(주) A attenuated porcine epidemic diarrhrea virus, an immunogenic composition comprising the same and a method for detecting the virus
KR101333852B1 (en) 2008-06-27 2013-11-27 조에티스 엘엘씨 Novel adjuvant compositions
CN104152578B (en) * 2013-06-03 2016-03-30 中国农业科学院上海兽医研究所 Porcine epidemic diarrhea virus RT-PCR differential diagnosis kit and application thereof
BR112016005948A2 (en) 2013-09-19 2017-09-26 Zoetis Services Llc oil based adjuvants
LT3166634T (en) * 2014-07-11 2021-11-10 Zoetis Services Llc Novel vaccine compositions for porcine epidemic diarrhea virus

Also Published As

Publication number Publication date
WO2017123201A1 (en) 2017-07-20
EP3402878A1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
CA3010977A1 (en) Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
WO2016007576A3 (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
JP2017035093A5 (en)
HRP20171213T1 (en) RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
CO2018005229A2 (en) Respiratory Syncytial Virus Vaccine
EP4104854A3 (en) Multivalent vaccines for rabies virus and coronaviruses
NZ591925A (en) Adjuvant composition comprising a host defense peptide, an immunostimulatory sequence and a polyanionic polymer
IL276210B2 (en) Mers-cov vaccine
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
EP4043031A3 (en) Zika viral antigen constructs
EA201590304A1 (en) VACCINE OF THE RECOMBINANT MODIFIED VIRUS OF ANPARA OSPOVAKCINA RESPIRATORY SYNCYIAL VIRUS
PH12019500592A1 (en) New swine influenza vaccine
EA201291373A1 (en) VACCINE AND METHODS TO ELIMINATE INFECTION CAUSED BY CAMPYLOBACTER
WO2016210083A3 (en) Inactivated canine influenza vaccines and methods of making and uses thereof
WO2013001285A3 (en) Fmdv vp1 peptides
CL2021003211A1 (en) A modified live strain of porcine reproductive and respiratory syndrome virus (prrs), a vaccine comprising it and its use to treat prrs type ii. (divisional application no. 2123-2018)
EA201991041A1 (en) VACCINE AGAINST PORK PARVOVIRUS AND PIG REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND METHODS FOR ITS PRODUCTION
RU2018116601A (en) Immunogenic Fusion Protein
PH12017500216B1 (en) Vaccine in serotype-9 fowl adenovirus recombinant vector
WO2016141338A3 (en) Marker system, in particular for baculovirus-expressed subunit antigens
HRP20211838T1 (en) Truncated rotavirus vp4 protein and application thereof
MX339731B (en) Infectious bronchitis vaccines derived from ib-qx-like strains.
AR097029A1 (en) ACCELERATION OF THE IMMUNE RESPONSE INDUCED BY VECTOR VIRUS IN BIRDS, COMPOSITION, USE, VACCINATION METHOD AND METHOD FOR ACCELERATING THE IMMUNE RESPONSE
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
MX2019007924A (en) Influenza vaccines.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180710

FZDE Dead

Effective date: 20201112